Spyre (SYRE) Jumps 42% as Treatment Candidate Shows ‘Best-in-Class’ Potential
Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the Ten stocks with monstrous returns. Spyre Therapeutics surged its stock price 42.3 percent week over week as investors took heart from the “best-in-class” potential of its ulcerative colitis (UC) therapy candidate. In a report updated earlier in the week, Spyre Therapeutics Inc. (NASDAQ:SYRE) said its treatment candidate,…